Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
CSL Delivers Healthy Product Growth
Aug 15 2013
CSL delivered a robust FY13 result. For brokers it’s all about balancing research investment with product growth.
Weekly Broker Wrap: Worries Grip Brokers As Earnings Season Ramps Up
Aug 09 2013
Brokers are worried about many things this earnings season, including life insurers, building, construction and industry, gas supply, consumer stocks, even banks.
Health Care Stable But Needs Monitoring
Aug 07 2013
Brokers preview the major health care sector stocks and find a less volatile earnings season on the cards.
Brokers Breathe Easier Over ResMed
Aug 06 2013
ResMed’s latest results and FY14 outlook highlight the strong margins that will stand the company in good stead.
GI Dynamics Sends Sugar Levels Racing
Jun 20 2013
Two brokers think Australian listed diabetes and weight loss company GI Dynamics is close to taking off.
Weekly Broker Wrap: Bank Bubble, Cautious Consumer, Tested Telecoms
Jun 17 2013
Bank valuations are becoming less stretched while retailers are still battling with a reluctant consumer. Telecoms are maturing and plasma is robust.
NIB Holdings On The Waiting List
Jun 13 2013
Contrary broker views on NIB Holdings reflect more of a timing issue to growth rather than disagreement over value.
Cochlear’s Now More Balanced
Jun 04 2013
Cochlear delivered the earnings estimate downgrade that brokers feared. Now that’s out of the way, the outlook is a little more rosy.
REVA Medical Opens Opportunity In Stent Market
Jun 03 2013
REVA Medical has commenced recruiting for a CE Mark trial of its new stent product, which has Bell Potter assessing the potential of the stock.
Low AUD A Positive Injection For Aussie Healthcare
Jun 03 2013
The low AUD is already impacting on the Australian Healthcare sector in terms of positive earnings forecast and target revisions.
